IP Library Granted Patent US 7,897,161
Granted Patent B2
US 7,897,161 · App. 10/516,657 · Granted Mar 1, 2011

External medicine for treating dermatitis

Assignee: CAC Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,897,161
App. No.
10/516,657
Granted
Mar 1, 2011
Kind
B2
Abstract

An external medicine for treating dermatitis wherein an adrenocortical steroid is included by a cyclodextrin; and 0.025 to 0.5% by weight of the adrenocortical steroid, 0.2 to 30% by weight of the cyclodextrin, and 0.5 to 55% by weight of dextran or pullulan are dissolved in an aqueous solution containing polysaccharide; and 0.5 to 55% by weight of xyloglucan, trehalose, laminaran, krestin, and pectin are blended. Grape sugar, mutan, lentinan, sodium chloride, and potassium chloride are comprised in the medicine. The medicine has a higher cure effect on atopic dermatitis and psoriasis vulgaris.

Claims (20)

1. An external medicine for treating atopic dermatitis and psoriasis vulgaris wherein the external medicine is an aqueous solution comprising:

0.025 to 0.5% by weight of adrenocortical steroid,

0.2 to 30% by weight of cyclodextrin,

0.5 to 55% by weight of a dextran or pullulan; and

0.5 to 55% by weight of each xyloglucan, trehalose, laminaran, krestin, and pectin;

and wherein the medicine then further comprises at least one selected from the group consisting of grape sugar, mutan, lentinan, sodium chloride, and potassium chloride.

2. The external medicine for treating atopic dermatitis and psoriasis vulgaris according to claim 1 , wherein the aqueous solution comprises said grape sugar and said sodium chloride.

3. The external medicine for treating atopic dermatitis and psoriasis vulgaris according to claim 1 , wherein the adrenocortical steroid is included in the cyclodextrin.

4. A method of treating dermatitis with an external medicine, wherein the external medicine is an aqueous solution comprising:

0.025 to 0.5% by weight of adrenocortical steroid;

0.2 to 30% by weight of cyclodextrin;

0.5 to 55% by weight of dextran or pullulan; and

0.5 to 55% by weight of each of xyloglucan, trehalose, laminaran, krestin and pectin,

and further comprising at least one selected from the group consisting of grape sugar, mutan, lentinan, sodium chloride and potassium chloride.

5. The treatment method according to claim 4 , wherein the dermatitis is selected from the group consisting of atopic dermatitis, seborrheic dermatitis, psoriasis vulgaris, eczema and acne.

6. The treatment method according to claim 4 , wherein the dermatitis is selected from the group consisting of atopic dermatitis and psorasis vulgaris.

7. The treatment method according to claim 4 , wherein the aqueous solution further comprises at least said grape sugar and said sodium chloride.

8. The treatment method according to claim 4 , wherein the adrenocortical steroid is included in the cyclodextrin.

9. The external medicine for treating atopic dermatitis and psoriasis vulgaris according to claim 1 , wherein the medicine does not contain an oil.

10. The treatment method according to claim 4 , wherein the medicine does not contain an oil.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2004
From: YAMADA, HAJIME; YAMADA, AKIRA
To: CAC CORPORATION
Reel/Frame 016469/0391 →
Priority Claims (1)
JP 2002-161000 · Jun 3, 2002 · national
Continuity (1)
Related Publication 20050175640A1 · Aug 11, 2005